Off-label use of dalbavancin in children: a case series.

Autor:	Gamell A; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain., Velasco-Arnaiz E; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain., López-Ramos MG; Pharmacy Department, Hospital Sant Joan de Déu, Barcelona, Spain., Ríos-Barnés M; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain., Simó-Nebot S; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain.; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain., Fumadó V; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain.; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Department of Paediatrics, University of Barcelona, Barcelona, Spain., Noguera-Julián A; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain.; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Department of Paediatrics, University of Barcelona, Barcelona, Spain.; Red de Investigación Translacional en Infectología Pediátrica (RITIP), Madrid, Spain., Fortuny C; Infectious Diseases Department, Hospital Sant Joan de Déu, Barcelona, Spain.; CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.; Department of Paediatrics, University of Barcelona, Barcelona, Spain.; Red de Investigación Translacional en Infectología Pediátrica (RITIP), Madrid, Spain.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Aug 01; Vol. 79 (8), pp. 2062-2067.
DOI:	10.1093/jac/dkae212
Abstrakt:	Introduction: Dalbavancin is an antibiotic active against most Gram-positive bacteria approved for acute bacterial skin and skin structure infections (ABSSSI). Owing to its long half-life, it is being increasingly used for other indications. Patients and Methods: We present a case series of children and adolescents treated with dalbavancin for osteoarticular, catheter-related and other non-ABSSSI infections. Results: Dalbavancin was prescribed to 15 patients. Six (40%) were female and median age at prescription was 11.9 (IQR 1.3-18.0) years. Most of them (12/15) had significant comorbidities. Patients presented mainly with deep surgical site infections, osteoarticular infections and central-line-associated bloodstream infections. The most common isolate was Staphylococcus aureus followed by Staphylococcus epidermidis. Major reasons to prescribe dalbavancin were to ensure compliance and patients' convenience. Two patients discontinued the drug due to adverse events possibly related to it. The rest of the patients completed the treatment with dalbavancin, with a median duration of 56 days (IQR 17.5, 115.5). All achieved complete resolution and present no relapse after a median follow-up of 9.9 months (IQR 4.8, 16.6). Conclusions: Dalbavancin was a safe, effective and convenient alternative in selected paediatric patients with complicated non-ABSSSI infections caused by Gram-positive bacteria. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu